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Abstract
Background: In order to define new prognostic subgroups in patients with glioblastoma a miRNA screen (> 1000
miRNAs) from paraffin tissues followed by a bio-mathematical analysis was performed.
Methods: 35 glioblastoma patients treated between 7/2005 - 8/2008 at a single institution with surgery and
postoperative radio(chemo)therapy were included in this retrospective analysis. For microarray analysis the febit
biochip “Geniom
® Biochip MPEA homo-sapiens” was used. Total RNA was isolated from FFPE tissue sections and
1100 different miRNAs were analyzed.
Results: It was possible to define a distinct miRNA expression pattern allowing for a separation of distinct
prognostic subgroups. The defined miRNA pattern was significantly associated with early death versus long-term
survival (split at 450 days) (p = 0.01). The pattern and the prognostic power were both independent of the MGMT
status.
Conclusions: At present, this is the first dataset defining a prognostic role of miRNA expression patterns in
patients with glioblastoma. Having defined such a pattern, a prospective validation of this observation is required.
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Introduction
Glioblastoma multiforme (GBM) is the most common
and aggressive primary brain tumor [1]. Malignant glio-
mas account for approximately 70% of new cases of
malignant primary brain tumors diagnosed in adults.
Median age at diagnosis of primary gliomas is 64 years
and malignant gliomas are more common in men than in
women [2].
Currently the treatment of GBM is based on a multi-
disciplinary approach including surgery and adjuvant
radiochemotherapy followed by maintenance che-
motherapy. Concomitant and adjuvant administration of
temozolomide improved 2-year survival of patients with
newly diagnosed malignant glioma (mainly GBM) from
11% to 27%, 3-year survival from 4% to 16% and 5-year
survival from 2% to 10% [3,4].
Despite all developments for primary and recurrent glio-
blastoma [3,5], there is still extreme room for further
improvement since glioblastoma has a dismal prognosis
for most of the patients with a high rate of local recur-
rences [6]. At present, several strategies may lead to an
optimization: Firstly, better imaging tools as well as
improved image-guidance are available [7-10] and dose
escalation while sparing normal tissue has been achieved
by new technical approaches such as intensity-modulated
radiotherapy [11], volumetric single arc technique [12] or
older techniques such as fractionated stereotactic boost/
r a d i o s u r g e r y[ 1 3 ] .S e c o n d l y ,i na d d i t i o nt oa ni m p r o v e d
application of radiotherapy, the combination of radiation
with targeted drugs may turn out to increase the therapeu-
tic ratio. In this regard different targeted molecules are
currently undergoing pre-clinical and clinical testing
[14-20].
Closely associated with the research fields mentioned
above, it is of crucial importance to gain insight into the
underlying biological reasons for different patient out-
comes. It is well known that the prognosis of patients
* Correspondence: claus.belka@med.uni-muenchen.de
† Contributed equally
1Department of Radiation Oncology, Ludwig-Maximilians-University Munich,
Marchioninistr. 15, 81377 Munich, Germany
Full list of author information is available at the end of the article
Niyazi et al. Radiation Oncology 2011, 6:153
http://www.ro-journal.com/content/6/1/153
© 2011 Niyazi et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.with glioblastoma differs considerably on an individual
scale [21].
At present only very few prognostic factors such as a
higher age or a bad ECOG score have been defined.
Recently, certain molecular pathways and associated
biomarkers have been established as prognostic and pre-
dictive markers. In this regard, Hegi et al. identified the
O6-methylguanine DNA-methyltransferase (MGMT) pro-
moter methylation status to be a potent prognostic factor
for GBM patients with a potential predictive value for the
efficacy of temozolomide-based radiochemotherapy
[22,23]. Additionally, IDH1 and IDH2 status have
recently been introduced in GBM but their predictive
role has not yet been defined though their prognostic
power is well-known [24,25]. However, neither MGMT
methylation nor other markers are precise enough to
enable individual assessments.
The use of microRNAs (miRNAs) as tumor biomarkers
has gained growing interest in the last few years. Accumu-
lating evidence indicates that miRNA expression can be
used as a prognostic and/or diagnostic marker for human
cancers [26]. The miRNAs consist of 18-25 nucleotides
and are a class of endogenous ribo-regulators that modu-
late gene expression via the RNA interference (RNAi)
pathway [27]. The discovery of miRNAs dates back to
1993 when Lee et al. described a small RNA, lineage-defi-
cient-4 (lin-4), with antisense complementarity to lin-14
involved in the regulation of developmental timing in Cae-
norhabditis elegans [28]. MicroRNA deregulation is impli-
cated in processes such as cell proliferation, cell cycle
regulation, apoptosis, invasion, glioma stem cell behavior
and angiogenesis [29,30].
More than 1000 microRNAs (miRNAs) are present in
the human genome. Expression is largely tissue and cell
type specific, with some miRNAs considered to be house-
keeping molecules. Each miRNA is predicted to target and
possibly regulate multiple mRNA species. Diverse high-
throughput screenings of various systems have as yet iden-
tified only a limited number of functional miRNAs [31].
Their role in regulating a great variety of targets and, as
a consequence, multiple pathways, makes their use in
diagnostics potentially a powerful tool to be exploited for
risk assessment and prognosis and for the design of inno-
vative therapeutic strategies [32].
With all the inherent limitations of a retrospective
analysis in mind, we have determined the prognostic
value of miRNA expression patterns for overall survival
in 35 primary glioblastoma patients who were treated at
our institution with radio(chemo)therapy following sur-
gery. Follow-up data and MGMT methylation status
were used to test whether miRNA profiles may be
MGMT-independent prognostic factors for overall
survival.
Patients and Methods
All glioblastoma patients treated with surgery and post-
operative radio(chemo)therapy treated between 7/2005
and 8/2008 at our institution were identified using the
departmental database. Radiochemotherapy with temo-
zolomide was applied according to the EORTC/NCIC
regimen [3,4].
Our study was approved by the local ethics committee
(No. 442-09), histopathologic diagnosis was confirmed
by central pathology review in all cases.
Determination of MGMT promoter methylation was
performed using both methylation-specific PCR and
sequencing analysis as being published before [33,34].
For miRNA analysis the biochip “Geniom
® Biochip
MPEA homo sapiens” from febit was used (Febit holding
GmbH, Im Neuenheimer Feld, Heidelberg, Germany).
The probes are designed as the reverse complements of
all major mature miRNAs and are based on sequences as
published in the current Sanger miRBase release (version
15.0 April 2010, see http://microrna.sanger.ac.uk/
sequences/index.shtml) for Homo sapiens. Additional
nucleotides are bound on the 5’end of each capture oligo-
nucleotide that serve as template for the enzymatic
extension in the labelling procedure. The probes are
synthesized with intra-array replicates to increase the sta-
tistical confidence and to compensate for potential posi-
tional effects. The intensities of blank probes consisting
only of one single “T” nucleotide are used for background
corrections.
Sample washing and detection
Total RNA was isolated from FFPE tissue sections using
the QIAGEN RNeasy FFPE Kit. For each array the RNA
was suspended in febit’s proprietary miRNA Hybridization
Buffer (25 μl per array). Hybridization was done automati-
cally for 16 h at 42°C using the Geniom RT
®-Analyzer.
After washing the chips were labelled using the microflui-
dic-based primer extension assay. This assay utilizes the
bound miRNAs as a primer for an enzymatic elongation
with biotinylated nucleotides. The elongation was done
using the Klenow polymerase I Fragment at 37°C for 15
minutes. Biotin incorporation was detected with streptavi-
din-phycoerythrin, in combination with febit’s consecutive
Signal Enhancement procedure. The feature recognition
(using Cy3 lter set) and signal calculation were done
automatically.
Clustering analysis
In order to define miRNA patterns similar clusters were
identified by hierarchical clustering. In this regard, a simi-
larity matrix was generated that contained all pairwise
similarities between probes or samples. The Euclidean dis-
tance was applied for the similarity measurement.
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matrix. This hierarchy is represented as a tree, a so-
called dendrogram. To compute the similarity between
two clusters complete linkage (distances of all pairs of
elements in both clusters) was applied.
As a final result, a heatmap was generated, i.e., a colored
representation of samples and probes, ordered by their
similarity with a dendrogram on top (clustering of sam-
ples) and on the right side (clustering of probes).
To detect possible clusters in rows (transcripts) and col-
umns (samples) of the normalized expression matrix we
carried out a bottom-up complete linkage clustering using
the Euclidean distance a measure.
Statistics
We performed all analyses using the Statistical Package for
Social Sciences (SPSS, Ver. 19.0, SPSS Inc, Chicago, IL).
Survival analyses were based on Kaplan-Meier estimates,
univariate testing was performed by means of the log-rank
test and Cox regression analysis was used to determine
hazard ratios as well as to perform a multivariate analysis.
The correlation between two dichotomous variables was
assessed using Fisher’s exact test. A two-tailed p-value ≤
0.05 was considered significant.
Results
Patient characteristics
We examined paraffin tissue samples of a non-selected
cohort of consecutively treated patients at the Ludwig-
Maximilians university hospital Munich, Großhadern from
7/2005 to 8/2008. Only patients with surgery and post-
operative radio(chemo)therapy were eligible. Median over-
all survival of the patient cohort was 530 days, median
follow-up was also 530 days including early deaths (range,
16 - 1545 days). MGMT status was available in 30 cases,
missing in five cases (see Table 1 for all baseline character-
istics). The attribution of RPA-classes in retrospect is diffi-
cult and therefore comprises some degree of uncertainty.
In 8 cases no definite assignment could be performed; the
majority of patients (85.2%) had RPA class IV and V [35].
Survival data and univariate analysis
In a first step, we determined whether a survival cutoff-
value, defined by the median survival within the
EORTC-NCIC trial 26981 of nearly 450 days, would
clearly separate long- and short-term survivors in our
analysis. The difference between long- and short-term
survival was significant (p < 0.001). Median overall sur-
vival was 990 days for long-term and 267 days for short-
term survivors; mean values were 1075 days and 244
days, respectively.
MGMT had a significant influence in the univariate
analysis on overall survival: p = 0.009, hazard ratio 3.6
(95%-CI 1.3 - 9.7) (Figure 1, Table 2). Median survival of
MGMT methylated patients was not defined, MGMT
not methylated patients had a median overall survival of
395 days. Mean values were 1010 days vs. 474 days. Data
of 5 patients could not be evaluated due to unknown
MGMT status.
The results of the univariate analysis for additional
prognostic factors such as sex, age (≥ 60 y, < 60 y), con-
comitant/adjuvant temozolomide, RPA class, type of
resection and re-irradiation are shown in Table 2. In
this regard, sex, re-irradiation, type of resection and age
category were non-significant factors, whereas the use of
temozolomide (concomitant and adjuvant) were signifi-
cant and RPA class marginally significant (p = 0.08).
Table 1 Baseline patient characteristics, N = 35, TMZ -
temozolomide
Characteristic Patients
MGMT methylation status
￿ methylated 17
￿ not methylated 13
￿ unknown 5
Median follow-up (range) 530 days (16 - 1545)
Sex
￿ male 22
￿ female 13
Median age (range) 62 (33 - 77)
Age
￿ <6 0y 1 4
￿ ≥ 60 y 21
Type of resection
￿ complete 18
￿ incomplete 17
RPA class
￿ III 4
￿ IV 11
￿ V1 2
￿ not exactly known 8
Re-RT
￿ yes 4
￿ no 31
Concomitant TMZ
￿ yes 26
￿ no 7
￿ unknown 2
Adjuvant TMZ
￿ yes 19
￿ no 14
￿ unknown 2
Survival
￿ long-term 20
￿ short-term 15
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For the detection of differentially regulated miRNAs, a
wide variety of measures had been proposed. These meth-
ods include quotation of mean, median, or variance, para-
metric t-test, non-parametric Wilcoxon-Mann-Whitney
test, Empirical Bayes Statistics and the area under the
receiver operator characteristics curve. For all significance
tests (t-test, Wilcoxon-Mann- Whitney test and Empirical
Bayes Statistics) the raw p-values are provided. However,
since multiple miRNAs are tested, these p-values must be
adjusted for multiple testing to control the False Discovery
Rate. Significantly deregulated miRNAs were miR-3163
(fold change 2.0, p = 0.05), miR-539 (fold change 0.5, p =
0.001), miR-1305 (fold change 0.5, p = 0.05), miR-1260
(fold change 0.5, p = 0.03) and let-7a (fold change 0.3, p =
0.02, in all cases unadjusted p-values; 30 most deregulated
probes).
Correlations and multivariate analysis
As seen in Figure 2, there are two branches of the den-
drogram, grouping 34 of the 35 samples into two
categories. These two groups show different expression
patterns of the 30 analyzed miRNAs (those which are
maximally deregulated). Most interestingly, these two
patterns correlate with survival (short-term vs. long-
term survival): p = 0.01 (Fisher’s exact test) but do not
correlate with the MGMT status (p = 0.5).
In order to examine the real influence of both patterns
on survival, Kaplan-Meier curves for both patterns were
plotted (see Figure 3). It could be shown that pattern 1/
2 was associated with increased/decreased survival, p =
0.006 in univariate analysis, hazard ratio 0.3 (95%-CI 0.1
- 0.7); median survival for pattern 1 was 990 days, for
pattern 2 it was 376 days. Mean values were 1053 days
(pattern 1) and 470 days (pattern 2).
Analyzing the slightly more homogeneous group of
patients who received concomitant temozolomide (N =
26) still revealed a significant result in univariate analysis
for the pattern 1/2 (p = 0.005, log-rank test) and there
was still no correlation between MGMT methylation sta-
tus of these patients and pattern 1/2 (p = 0.2).
When performing a multivariate analysis for all patients
including the factors MGMT status, miRNA pattern, adju-
vant temozolomide, age category and RPA class, it turns
out that only adjuvant temozolomide remains a prognostic
factor (p = 0.01), MGMT status and miRNA pattern lose
their prognostic significance (p = 0.17 and p = 0.22).
Discussion
In order to define new marker constellations for a more
precise separation of different prognostic groups in
patients with GBM we performed a miRNA array analy-
sis including merely all currently known miRNAs.
In our analysis, two complementarily defined miRNA
pattern predicted early death versus long-term survival
(split at 450 days) in a significant way (p = 0.01) and this
prediction was independent of the MGMT status. Thus,
importantly the miRNA pattern was correlated with out-
come independently of the MGMT status within the uni-
variate analysis. This could not be proven within the
multivariate analysis due to statistical limitations as the
case number and the number of events was too small.
Number at risk
methylated 17 13 12 8 4 1 1 0
notmethylated 13 12 6 2 0 0 0 0
Figure 1 Kaplan-Meier overall survival curves for MGMT
methylated (N = 17) or MGMT not methylated (N = 13)
patients. Significant difference by log-rank test (p = 0.009).
Table 2 Univariate analysis on potential prognostic factors for overall survival after primary diagnosis, ns - not
significant, CI - confidence interval, meth - methylated
Factor p-value (unadjusted, log-rank) Hazard ratio 95%-CI
MGMT methylation status (not meth/meth) 0.009 3.6 1.3 - 9.7
Sex (male/female) ns (0.4) 1.2 0.8 - 1.8
Re-RT (no/yes) ns (0.5) 1.7 0.4 - 7.0
Concomitant TMZ (no/yes) 0.04 2.6 1.0 - 6.8
Adjuvant TMZ (no/yes) 0.001 4.1 1.7 - 9.8
Age category (< 60 y, ≥ 60 y) ns (0.1) 0.5 0.2 - 1.2
Type of resection (complete/incomplete) ns (0.83) 0.9 0.4 - 2.0
RPA class (V/IV/III) ns (0.08) IV (0.5), III (0.2) IV (0.2 - 1.2), III (0.02 - 1.4)
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of the regulatory network involved in tumor gene
expression are at least as important as a single distur-
bance of a single DNA repair enzyme.
At present, the role of individual miRNAs in GBM is
poorly understood. MiRNAs are small noncoding
regulatory RNAs that reduce stability and/or translation
of fully or partially sequence-complementary target
mRNAs [36]. In this sense, they are important post-tran-
scriptional gene regulators and play an important role in
response to cellular stress [37] as well as pathogenesis of
cancer development and progression [38] with miR-17
S L L S S L L L L L L L L L L S S L L S S S L L SS L S L L SS S S L
Pattern 1 Pattern 2
Figure 2 Heatmap with dendrograms for comparison short-term (S) vs. long-term survivor (L).
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gression [39].
It has been shown recently that GBMs display a distinct
miRNA expression signature and a number of recent stu-
dies have linked these miRNA alterations to key hall-
marks of GBM including proliferation, survival, invasion,
angiogenesis and stem cell-like behavior [40,41]. More-
over, resistance to temozolomide might be associated
with miRNA deregulation [42]. In this regard, Ciafre et
al. studied the global expression of 245 microRNAs in
GBM using a microarray technique [43] in comparison
to normal brain tissue. This approach enabled the identi-
fication of miRNAs whose expression is significantly
altered in tumors compared with peripheral brain areas
from the same patient, including miR-221, strongly up-
regulated in GBM, and a set of brain-enriched miRNAs,
miR-128, miR-181a, miR-181b, and miR-181c, which
were down-regulated in glioblastoma [36].
In contrast to the available data on miRNA in GBM, our
approach differed significantly. Based on the hypothesis
that an equally complex network of different miRNAs
might regulate complex metabolic interactions regulating
processes such as the therapy response in tumor cells we
speculated that a fingerprinting approach using biological
extremes would reveal informative prognostic data. Indeed
our approach revealed a miRNA pattern being significantly
associated with the outcome of the pre-defined biological
extremes.
However, at present one has to bear in mind that the
approach chosen is purely retrospective and does not
contain a control group of uninvolved brain parenchyma.
It is only useful to generate a hypothesis but not to prove
a predictive character of the observed miRNA pattern.
Thus it is mandatory to validate the miRNA pattern in a
prospective trial.
Besides the validation of the given pattern, it is of
major interest to understand to role of individual
miRNAs for the biological response of GBM. Among
the panel of miRNAs, there are some with relatively
unknown cell cycle function, such as miR-3163, miR-
1305, miR-1260. Others have already been examined on
a functional level such as miR-539 which is among the
factors sensing biotin and regulating holocarboxylase
synthetase. This enzyme plays an essential role in cata-
lyzing the biotinylation of carboxylases and histones.
Biotinylated carboxylases are needed for the metabolism
of glucose, lipids and leucine; biotinylation of histones
plays important roles in gene regulation and genome
stability [44]. The most prominently deregulated miRNA
is let-7a: Lethal-7a was recently found to be associated
with several cancers, such as lung and colon cancers. It
was also proposed that let-7a may be a tumor suppres-
sor in laryngeal cancer by inhibiting cell growth, indu-
cing cell apoptosis and down-regulating oncogene
expression; in Hep-2 cells, let-7a induced apoptosis and
d o w n r e g u l a t e dR A Sa n dc - M Y Cp r o t e i ne x p r e s s i o n
without affecting the mRNA levels [45]. But none of
these miRNAs has been linked to glioblastoma up to
now.
Conclusions
This study is - to our best knowledge - the first clinical
miRNA screening trial in GBM patients resulting in the
definition of a distinct miRNA pattern. This pattern
may serve as potential new prognostic and/or predictive
marker set allowing for patient stratification indepen-
dent of the MGMT status. Although the trial was based
on a small sample size and is limited by the retrospec-
tive character of the study, the data urgently mandate a
prospective validation and additional research in order
to define to biological role of miRNA alteration for the
pathogenesis of glioblastoma.
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